Ryman Healthcare Ltd
RYM: XNZE (NZL)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
NZD 3.20 | Qvmmwf | Lnykqbjq |
Ryman Healthcare: Firmer House Prices and Population Growth Suggest Recovery Potential
Narrow-moat-rated Ryman Healthcare faced significant challenges in recent years, but we see signs of conditions stabilizing. We maintain our fair value estimate at NZD 10 per security. The securities screen as significantly undervalued.